Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 84 articles:
HTML format



Single Articles


    October 2021
  1. CHERADAME L, Guerrera IC, Gaston J, Schmitt A, et al
    STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway.
    Oncogene. 2021 Oct 8. pii: 10.1038/s41388-021-02037.
    PubMed     Abstract available


  2. BLOCK CJ, Mitchell AV, Wu L, Glassbrook J, et al
    RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA.
    Oncogene. 2021 Oct 4. pii: 10.1038/s41388-021-02030.
    PubMed     Abstract available


    September 2021
  3. LIU Z, Sang X, Wang M, Liu Y, et al
    Melatonin potentiates the cytotoxic effect of Neratinib in HER2(+) breast cancer through promoting endocytosis and lysosomal degradation of HER2.
    Oncogene. 2021 Sep 23. pii: 10.1038/s41388-021-02015.
    PubMed     Abstract available


  4. VAFAIZADEH V, Buechel D, Rubinstein N, Kalathur RKR, et al
    The interactions of Bcl9/Bcl9L with beta-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
    Oncogene. 2021 Sep 20. pii: 10.1038/s41388-021-02016.
    PubMed     Abstract available


    August 2021
  5. SUN J, Gaidosh G, Xu Y, Mookhtiar A, et al
    RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells.
    Oncogene. 2021 Aug 9. pii: 10.1038/s41388-021-01985.
    PubMed     Abstract available


  6. ZHANG F, Li P, Liu S, Yang M, et al
    beta-Catenin-CCL2 feedback loop mediates crosstalk between cancer cells and macrophages that regulates breast cancer stem cells.
    Oncogene. 2021 Aug 3. pii: 10.1038/s41388-021-01986.
    PubMed     Abstract available


  7. YAN Y, Narayan A, Cho S, Cheng Z, et al
    CRYbetaB2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer.
    Oncogene. 2021 Aug 2. pii: 10.1038/s41388-021-01975.
    PubMed     Abstract available


    July 2021
  8. ZHANG S, Guo X, Liu X, Zhong Z, et al
    Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation.
    Oncogene. 2021 Jul 30. pii: 10.1038/s41388-021-01970.
    PubMed     Abstract available


  9. WHATELY KM, Voronkova MA, Maskey A, Gandhi J, et al
    Nuclear Aurora-A kinase-induced hypoxia signaling drives early dissemination and metastasis in breast cancer: implications for detection of metastatic tumors.
    Oncogene. 2021 Jul 29. pii: 10.1038/s41388-021-01969.
    PubMed     Abstract available


  10. SETO-TETSUO F, Arioka M, Miura K, Inoue T, et al
    DIF-1 inhibits growth and metastasis of triple-negative breast cancer through AMPK-mediated inhibition of the mTORC1-S6K signaling pathway.
    Oncogene. 2021 Jul 24. pii: 10.1038/s41388-021-01958.
    PubMed     Abstract available


  11. ZHANG Y, Shi G, Zhang H, Xiong Q, et al
    Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway.
    Oncogene. 2021 Jul 16. pii: 10.1038/s41388-021-01944.
    PubMed     Abstract available


  12. CLEMENTS ME, Holtslander L, Edwards C, Todd V, et al
    HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer.
    Oncogene. 2021 Jul 10. pii: 10.1038/s41388-021-01931.
    PubMed     Abstract available


  13. YU P, Zhu X, Zhu JL, Han YB, et al
    The Chk2-PKM2 axis promotes metabolic control of vasculogenic mimicry formation in p53-mutated triple-negative breast cancer.
    Oncogene. 2021 Jul 9. pii: 10.1038/s41388-021-01933.
    PubMed     Abstract available


  14. HAMALIAN S, Guth R, Runa F, Sanchez F, et al
    A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers.
    Oncogene. 2021 Jul 8. pii: 10.1038/s41388-021-01906.
    PubMed     Abstract available


    June 2021
  15. QIU Y, Yang Y, Yang R, Liu C, et al
    Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
    Oncogene. 2021 Jun 25. pii: 10.1038/s41388-021-01896.
    PubMed     Abstract available


  16. BI X, Lou P, Song Y, Sheng X, et al
    Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway.
    Oncogene. 2021 Jun 21. pii: 10.1038/s41388-021-01873.
    PubMed     Abstract available


  17. SHARIATI M, Evans KW, Zheng X, Bristow CA, et al
    Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
    Oncogene. 2021 Jun 9. pii: 10.1038/s41388-021-01819.
    PubMed     Abstract available


  18. TRUONG TH, Benner EA, Hagen KM, Temiz NA, et al
    PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER(+) breast cancer.
    Oncogene. 2021 Jun 8. pii: 10.1038/s41388-021-01871.
    PubMed     Abstract available


  19. QIAO Y, Jin T, Guan S, Cheng S, et al
    Long non-coding RNA Lnc-408 promotes invasion and metastasis of breast cancer cell by regulating LIMK1.
    Oncogene. 2021 Jun 2. pii: 10.1038/s41388-021-01845.
    PubMed     Abstract available


    May 2021
  20. LODILLINSKY C, Fuhrmann L, Irondelle M, Pylypenko O, et al
    Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance.
    Oncogene. 2021 May 19. pii: 10.1038/s41388-021-01826.
    PubMed     Abstract available


  21. XU Q, Zhang J, Telfer BA, Zhang H, et al
    The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion.
    Oncogene. 2021 May 12. pii: 10.1038/s41388-021-01798.
    PubMed     Abstract available


  22. LAGER TW, Conner C, Keating CR, Warshaw JN, et al
    Cell surface GRP78 and Dermcidin cooperate to regulate breast cancer cell migration through Wnt signaling.
    Oncogene. 2021 May 12. pii: 10.1038/s41388-021-01821.
    PubMed     Abstract available


  23. WILLIAMS CB, Phelps-Polirer K, Dingle IP, Williams CJ, et al
    Correction: HUNK phosphorylates EGFR to regulate breast cancer metastasis.
    Oncogene. 2021 May 6. pii: 10.1038/s41388-021-01797.
    PubMed    


  24. STEBBING J, Zhang H, Xu Y, Lit LC, et al
    Correction: KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.
    Oncogene. 2021 May 4. pii: 10.1038/s41388-021-01794.
    PubMed    


    April 2021
  25. LIU L, Zhang X, Ding H, Liu X, et al
    Arginine and lysine methylation of MRPS23 promotes breast cancer metastasis through regulating OXPHOS.
    Oncogene. 2021 Apr 29. pii: 10.1038/s41388-021-01785.
    PubMed     Abstract available


  26. STEBBING J, Zhang H, Xu Y, Lit LC, et al
    Correction to: KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.
    Oncogene. 2021 Apr 22. pii: 10.1038/s41388-021-01759.
    PubMed    


  27. TRAPHAGEN NA, Hosford SR, Jiang A, Marotti JD, et al
    High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
    Oncogene. 2021 Apr 19. pii: 10.1038/s41388-021-01782.
    PubMed     Abstract available


  28. KIM ES, Nam SM, Song HK, Lee S, et al
    CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity.
    Oncogene. 2021 Apr 8. pii: 10.1038/s41388-021-01758.
    PubMed     Abstract available


    March 2021
  29. LIANG Y, Song X, Li Y, Su P, et al
    Correction: circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer.
    Oncogene. 2021 Mar 25. pii: 10.1038/s41388-021-01750.
    PubMed    


  30. WANG X, Feng M, Xiao T, Guo B, et al
    BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.
    Oncogene. 2021 Mar 25. pii: 10.1038/s41388-021-01756.
    PubMed     Abstract available


  31. HUTCHINSON SA, Websdale A, Cioccoloni G, Roberg-Larsen H, et al
    Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer.
    Oncogene. 2021 Mar 19. pii: 10.1038/s41388-021-01720.
    PubMed     Abstract available


  32. WANG YH, Chan YT, Hung TH, Hung JT, et al
    Transmembrane and coiled-coil domain family 3 (TMCC3) regulates breast cancer stem cell and AKT activation.
    Oncogene. 2021 Mar 19. pii: 10.1038/s41388-021-01729.
    PubMed     Abstract available


  33. MARTINEZ-ORDONEZ A, Seoane S, Avila L, Eiro N, et al
    POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation.
    Oncogene. 2021 Mar 13. pii: 10.1038/s41388-021-01740.
    PubMed     Abstract available


  34. CHEN T, Wang X, Li C, Zhang H, et al
    CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation.
    Oncogene. 2021 Mar 13. pii: 10.1038/s41388-021-01739.
    PubMed     Abstract available


  35. KIM H, Son S, Ko Y, Shin I, et al
    CTGF regulates cell proliferation, migration, and glucose metabolism through activation of FAK signaling in triple-negative breast cancer.
    Oncogene. 2021 Mar 10. pii: 10.1038/s41388-021-01731.
    PubMed     Abstract available


  36. BERDIEL-ACER M, Maia A, Hristova Z, Borgoni S, et al
    Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts.
    Oncogene. 2021 Mar 10. pii: 10.1038/s41388-021-01719.
    PubMed     Abstract available


  37. JALALIRAD M, Haddad TC, Salisbury JL, Radisky D, et al
    Aurora-A kinase oncogenic signaling mediates TGF-beta-induced triple-negative breast cancer plasticity and chemoresistance.
    Oncogene. 2021 Mar 5. pii: 10.1038/s41388-021-01711.
    PubMed     Abstract available


  38. REINSBOROUGH CW, Ipas H, Abell NS, Gouws EB, et al
    BCDIN3D RNA methyltransferase stimulates Aldolase C expression and glycolysis through let-7 microRNA in breast cancer cells.
    Oncogene. 2021 Mar 4. pii: 10.1038/s41388-021-01702.
    PubMed     Abstract available


  39. SIRKISOON SR, Carpenter RL, Rimkus T, Doheny D, et al
    Correction: TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment.
    Oncogene. 2021 Mar 2. pii: 10.1038/s41388-020-01620.
    PubMed    


  40. GE LP, Jin X, Yang YS, Liu XY, et al
    Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.
    Oncogene. 2021 Mar 2. pii: 10.1038/s41388-021-01655.
    PubMed     Abstract available


  41. VARONE E, Decio A, Chernorudskiy A, Minoli L, et al
    The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions.
    Oncogene. 2021;40:1721-1736.
    PubMed     Abstract available


  42. AHMED SF, Buetow L, Gabrielsen M, Lilla S, et al
    E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
    Oncogene. 2021;40:2149-2164.
    PubMed     Abstract available


  43. LIN CC, Yang WH, Lin YT, Tang X, et al
    DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.
    Oncogene. 2021;40:2018-2034.
    PubMed     Abstract available


    February 2021
  44. WU R, Li K, Yuan M, Luo KQ, et al
    Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells.
    Oncogene. 2021 Feb 24. pii: 10.1038/s41388-021-01691.
    PubMed     Abstract available


  45. BUTTI R, Nimma R, Kundu G, Bulbule A, et al
    Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression.
    Oncogene. 2021 Feb 18. pii: 10.1038/s41388-021-01663.
    PubMed     Abstract available


  46. WANG G, Wang J, Chang A, Cheng D, et al
    Correction to: Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2.
    Oncogene. 2021 Feb 10. pii: 10.1038/s41388-021-01652.
    PubMed    


  47. KUNG CP, Cottrell KA, Ryu S, Bramel ER, et al
    Correction to: Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer.
    Oncogene. 2021 Feb 9. pii: 10.1038/s41388-021-01669.
    PubMed    


  48. PAN JK, Lin CH, Kuo YL, Ger LP, et al
    MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer.
    Oncogene. 2021 Feb 3. pii: 10.1038/s41388-021-01654.
    PubMed     Abstract available


  49. CHEN D, Parker TM, Bhat-Nakshatri P, Chu X, et al
    Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression.
    Oncogene. 2021;40:1332-1346.
    PubMed     Abstract available


  50. AL-AKHRASS H, Conway JRW, Poulsen ASA, Paatero I, et al
    A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance.
    Oncogene. 2021;40:1300-1317.
    PubMed     Abstract available


  51. GU G, Tian L, Herzog SK, Rechoum Y, et al
    Hormonal modulation of ESR1 mutant metastasis.
    Oncogene. 2021;40:997-1011.
    PubMed     Abstract available


    January 2021
  52. ABRIL YLN, Fernandez IR, Hong JY, Chiang YL, et al
    Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer.
    Oncogene. 2021 Jan 21. pii: 10.1038/s41388-020-01637.
    PubMed     Abstract available


  53. ZHU P, He F, Hou Y, Tu G, et al
    A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability.
    Oncogene. 2021 Jan 19. pii: 10.1038/s41388-020-01638.
    PubMed     Abstract available


  54. ZHANG H, Wong CCL, Wei H, Gilkes DM, et al
    Correction: HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs.
    Oncogene. 2021 Jan 15. pii: 10.1038/s41388-020-01618.
    PubMed    


  55. VARESLIJA D, Ward E, Purcell SP, Cosgrove NS, et al
    Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01606.
    PubMed     Abstract available


  56. PANTANO F, Croset M, Driouch K, Bednarz-Knoll N, et al
    Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01603.
    PubMed     Abstract available


  57. YOUSEFI H, Vatanmakanian M, Mahdiannasser M, Mashouri L, et al
    Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01588.
    PubMed     Abstract available


  58. TIEDE S, Kalathur RKR, Luond F, von Allmen L, et al
    Multi-color clonal tracking reveals intra-stage proliferative heterogeneity during mammary tumor progression.
    Oncogene. 2021;40:12-27.
    PubMed     Abstract available


    December 2020
  59. KONG D, Zhou H, Neelakantan D, Hughes CJ, et al
    VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk.
    Oncogene. 2020 Dec 9. pii: 10.1038/s41388-020-01539.
    PubMed     Abstract available


  60. HAN J, Qu H, Han M, Ding Y, et al
    MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer.
    Oncogene. 2020 Dec 3. pii: 10.1038/s41388-020-01574.
    PubMed     Abstract available


  61. SONG Y, Zeng S, Zheng G, Chen D, et al
    FOXO3a-driven miRNA signatures suppresses VEGF-A/NRP1 signaling and breast cancer metastasis.
    Oncogene. 2020 Dec 1. pii: 10.1038/s41388-020-01562.
    PubMed     Abstract available


    November 2020
  62. ATTALLA S, Taifour T, Bui T, Muller W, et al
    Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo.
    Oncogene. 2020 Nov 24. pii: 10.1038/s41388-020-01560.
    PubMed     Abstract available


  63. GUAN X, Deng H, Choi UL, Li Z, et al
    EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis.
    Oncogene. 2020;39:7127-7141.
    PubMed     Abstract available


    October 2020
  64. ABDULLAH A, Akhand SS, Paez JSP, Brown W, et al
    Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer.
    Oncogene. 2020 Oct 30. pii: 10.1038/s41388-020-01530.
    PubMed     Abstract available


  65. KUNG CP, Cottrell KA, Ryu S, Bramel ER, et al
    Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer.
    Oncogene. 2020 Oct 27. pii: 10.1038/s41388-020-01515.
    PubMed     Abstract available


  66. ZHENG X, Lu S, He Z, Huang H, et al
    MCU-dependent negative sorting of miR-4488 to extracellular vesicles enhances angiogenesis and promotes breast cancer metastatic colonization.
    Oncogene. 2020 Oct 16. pii: 10.1038/s41388-020-01514.
    PubMed     Abstract available


  67. LI Y, Li L, Qin J, Wu J, et al
    OSR1 phosphorylates the Smad2/3 linker region and induces TGF-beta1 autocrine to promote EMT and metastasis in breast cancer.
    Oncogene. 2020 Oct 13. pii: 10.1038/s41388-020-01499.
    PubMed     Abstract available


  68. ZHANG L, Qin Y, Wu G, Wang J, et al
    PRRG4 promotes breast cancer metastasis through the recruitment of NEDD4 and downregulation of Robo1.
    Oncogene. 2020 Oct 9. pii: 10.1038/s41388-020-01494.
    PubMed     Abstract available


  69. CHEN H, Libring S, Ruddraraju KV, Miao J, et al
    SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer.
    Oncogene. 2020 Oct 8. pii: 10.1038/s41388-020-01488.
    PubMed     Abstract available


  70. WANG S, Somisetty VS, Bai B, Chernukhin I, et al
    The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen.
    Oncogene. 2020;39:6300-6312.
    PubMed     Abstract available


    September 2020
  71. WANG G, Wang J, Chang A, Cheng D, et al
    Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01481.
    PubMed     Abstract available


  72. ZHU J, Li X, Su P, Xue M, et al
    The ubiquitin ligase RNF181 stabilizes ERalpha and modulates breast cancer progression.
    Oncogene. 2020 Sep 24. pii: 10.1038/s41388-020-01464.
    PubMed     Abstract available


  73. LI LY, Chen XS, Wang KS, Guan YD, et al
    RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKalpha2-mediated autophagy.
    Oncogene. 2020 Sep 21. pii: 10.1038/s41388-020-01447.
    PubMed     Abstract available


    August 2020
  74. WANG M, Long K, Li E, Li L, et al
    DNA polymerase beta modulates cancer progression via enhancing CDH13 expression by promoter demethylation.
    Oncogene. 2020;39:5507-5519.
    PubMed     Abstract available


    July 2020
  75. CHAI TF, Manu KA, Casey PJ, Wang M, et al
    Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal.
    Oncogene. 2020;39:5373-5389.
    PubMed     Abstract available


    June 2020
  76. AL-ZAHRANI KN, Abou-Hamad J, Cook DP, Pryce BR, et al
    Loss of the Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers.
    Oncogene. 2020;39:4592-4602.
    PubMed     Abstract available


  77. TABATABAEIAN H, Rao A, Ramos A, Chu T, et al
    The emerging roles of WBP2 oncogene in human cancers.
    Oncogene. 2020;39:4621-4635.
    PubMed     Abstract available


  78. PANCHOLI S, Ribas R, Simigdala N, Schuster E, et al
    Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
    Oncogene. 2020;39:4781-4797.
    PubMed     Abstract available


    April 2020
  79. KLUZ PN, Kolb R, Xie Q, Borcherding N, et al
    Cancer cell-intrinsic function of CD177 in attenuating beta-catenin signaling.
    Oncogene. 2020;39:2877-2889.
    PubMed     Abstract available


  80. JEANNOT E, Darrigues L, Michel M, Stern MH, et al
    A single droplet digital PCR for ESR1 activating mutations detection in plasma.
    Oncogene. 2020;39:2987-2995.
    PubMed     Abstract available


  81. FRANCART ME, Vanwynsberghe AM, Lambert J, Bourcy M, et al
    Vimentin prevents a miR-dependent negative regulation of tissue factor mRNA during epithelial-mesenchymal transitions and facilitates early metastasis.
    Oncogene. 2020;39:3680-3692.
    PubMed     Abstract available


    March 2020
  82. HSU BE, Roy J, Mouhanna J, Rayes RF, et al
    C3a elicits unique migratory responses in immature low-density neutrophils.
    Oncogene. 2020;39:2612-2623.
    PubMed     Abstract available


  83. BRUMMER G, Fang W, Smart C, Zinda B, et al
    CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments.
    Oncogene. 2020;39:2275-2289.
    PubMed     Abstract available


    February 2020
  84. LEFORT S, Tan S, Balani S, Rafn B, et al
    Initiation of human mammary cell tumorigenesis by mutant KRAS requires YAP inactivation.
    Oncogene. 2020;39:1957-1968.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: